Feasibility, Tolerability, Safety and Efficacy of a Pantothenic Acid Based Dietary Supplement in Subjects with Mild to Moderate Facial Acne Blemishes

Jillian L. Capodice

Nutraceutical Medical Research, New York City, USA.

DOI: 10.4236/jcdsa.2012.23026                

Abstract

Objective: It has been suggested that pantothenic acid may have antibacterial and skin softening activity. The aim of this study was to explore the feasibility, tolerability, safety and preliminary efficacy of oral administration of a dietary supplement containing pantothenic acid in healthy human males and females with mild to moderate facial acne vulgaris. Methods: An open-label, single arm study of healthy adults who had been previously diagnosed with mild to moderate acne vulgaris was performed. Subjects were asked to take the study agent, a dietary supplement containing pantothenic acid, for eight weeks. The primary endpoint of the study was to assess the feasibility of oral administration of the study agent in subjects over an eight week period. Safety and tolerability were measured utilizing the assessment of adverse events by the National Cancer Institute’s Common Criteria for Adverse Event Reporting. Secondary endpoints measuring the efficacy of an oral panthothetic acid dietary supplement for the treatment of mild to moderate facial acne utilized changes in the extent of global facial skin blemishes, assessment of quality of life utilizing the Dermatology Life Quality Index (DLQI) and analysis of questions about the subject's beliefs and attitudes towards skin care and lifestyle. Results: Eleven subjects were enrolled and ten completed the study (90.9%). There were no reported adverse events. Of the 10 evaluable subjects, the average age (mean ± SD) was 31.8 ± 8. Analysis of the global number of skin blemishes demonstrated a significant mean reduction in lesion count following the use of the study agent at week 8 (endpoint) (11.18 ± 6.38, p = 0.02) compared to the average number of baseline blemishes (20.45 ± 10.44). DLQI scores were significantly lower at week 8 vs. baseline (p = 0.0194). Conclusions: The results from this study indicated that the administration of a pantothenic based dietary supplement in healthy human adults with mild to moderate acne vulgaris is feasible, safe and well tolerated. Secondary analysis shows that administration of the study agent significantly reduced global facial blemishes. Further randomized, placebo-controlled trials are warranted.

Keywords

Pantothenic Acid; Dietary Supplement; Facial Blemishes; Acne

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	S. Knutsen-Larson, A. L. Dawson, C. A. Dunnick and R. P. Dellavalle, “Acne Vulgaris: Pathogenesis, Treatment, and Needs Assessment,” Dermatologic Clinics, Vol. 30, No. 1, 2012, pp. 99-106, viii-ix. doi:10.1016/j.det.2011.09.001
[2]	L. E. Barnes, M. M. Levender, A. B. Fleischer Jr. and S. R. Feldman, “Quality of Life Measures for Acne Patients,” Dermatologic Clinics, Vol. 30, No. 2, 2012, pp. 293-300. doi:10.1016/j.det.2011.11.001
[3]	H. C. Williams, R. P. Dellavalle and S. Garner, “Acne Vulgaris,” The Lancet, Vol. 379, No. 9813, 2012, pp. 361-372. doi:10.1016/S0140-6736(11)60321-8
[4]	P. J. Magin, J. Adams, G. S. Heading, D. C. Pond and W. Smith, “Complementary and Alternative Medicine Therapies in Acne, Psoriasis, and Atopic Eczema: Results of a Qualitative Study of Patients’ Experiences and Perceptions,” Journal of Alternative and Complementary Medicine, Vol. 12, No. 5, 2006, pp. 451-457. doi:10.1089/acm.2006.12.451
[5]	Z. El-Akawi, N. Abdel-Latif and K. Abdul-Razzak, “Does the Plasma Level of Vitamins A and E Affect Acne Condition?” Clinical and Experimental Dermatology, Vol. 31, No. 3, 2006, p. 430. doi:10.1111/j.1365-2230.2006.02106.x
[6]	A. Y. Finlay and G. K. Khan, “Dermatology Life Quality Index (DLQI)—A Simple Practical Measure for Routine Clinical Use,” Clinical and Experimental Dermatology, Vol. 19, No. 3, 1994, pp. 210-216. doi:10.1111/j.1365-2230.1994.tb01167.x
[7]	F. B. Camargo Jr., L. R. Gaspar and P. M. Maia Campos, “Skin Moisturizing Effects of Panthenol-Based Formulations,” Journal of Cosmetic Science, Vol. 62, No. 4, 2011, pp. 361-370.
[8]	H. R. Jerajani, H. Mizoguchi, J. Li, D. J. Whittenbarger and M. J. Marmor, “The Effects of a Daily Facial Lotion Containing Vitamins B3 and E and Provitamin B5 on the Facial Skin of Indian Women: A Randomized, Double-Blind Trial,” Indian Journal of Dermatology, Venereology and Leprology, Vol. 76, No. 1, 2010, pp. 20-26. doi:10.4103/0378-6323.58674
[9]	G. S. Kelly, “Pantothenic Acid. Monograph,” Alternative Medicine Review, Vol. 16, No. 3, 2011, pp. 263-274.
[10]	D. Kobayashi, M. Kusama, M. Onda and N. Nakahata, “The Effect of Pantothenic Acid Deficiency on Keratinocyte Proliferation and the Synthesis of Keratinocyte Growth Factor and Collagen in Fibroblasts,” Journal of Pharmacological Sciences, Vol. 115, No. 2, 2011, pp. 230-234. doi:10.1254/jphs.10224SC
[11]	B. R. Eissenstat, B. W. Wyse and R. G. Hansen, “Pantothenic Acid Status of Adolescents,” The American Journal of Clinical Nutrition, Vol. 44, No. 6, 1986, pp. 931-937.
[12]	H. P. Gollnick, A. Y. Finlay and N. Shear, “Global Alliance to Improve Outcomes in Acne. Can we Define Acne as a Chronic Disease? If So, How and When?” American Journal of Clinical Dermatology, Vol. 9, No. 5, 2008, pp. 279-284. doi:10.2165/00128071-200809050-00001
[13]	L. H. Leung, “Pantothenic Acid Deficiency as the Pathogenesis of Acne Vulgaris,” Medical Hypotheses, Vol. 44, No. 6, 1995, pp. 490-492. doi:10.1016/0306-9877(95)90512-X
[14]	R. I. Peirano, T. Hamann, H. J. Dusing, M. Akhiani, U. Koop, T. Schmidt-Rose and H. Wenck, “Topically Applied L-Carnitine Effectively Reduces Sebum Secretion in Human Skin,” Journal of Cosmetic Dermatology, Vol. 11, No. 1, 2012, pp. 30-36. doi:10.1111/j.1473-2165.2011.00597.x
[15]	J. R. Ingram, D. J. Grindlay and H. C. Williams, “Management of Acne Vulgaris: An Evidence-Based Update,” Clinical and Experimental Dermatology, Vol. 35, No. 4, 2010, pp. 351-354. doi:10.1111/j.1365-2230.2009.03683.x